Literature DB >> 15908628

Isoniazid pharmacokinetics in children treated for respiratory tuberculosis.

H S Schaaf1, D P Parkin, H I Seifart, C J Werely, P B Hesseling, P D van Helden, J S Maritz, P R Donald.   

Abstract

AIMS: To define the pharmacokinetics of isoniazid (INH) in children with tuberculosis in relation to the N-acetyltransferase 2 (NAT2) genotype.
METHODS: The first order elimination rate constant (k) and area under the concentration curve (AUC) were calculated in 64 children <13 years of age (median 3.8) with respiratory tuberculosis from INH concentrations determined 2-5 hours after a 10 mg/kg INH dose. The NAT2 genotype was determined; 25 children were classified as homozygous slow (SS), 24 as heterozygous fast (FS), and 15 as homozygous fast (FF) acetylators.
RESULTS: The mean (SD) k values of the genotypes differed significantly from one another: SS 0.254 (0.046), FS 0.513 (0.074), FF 0.653 (0.117). Within each genotype a median regression of k on age showed a significant decrease in k with age. The mean (SD) INH concentrations (mg/l) two hours after INH administration were SS 8.599 (1.974), FS 5.131 (1.864), and FF 3.938 (1.754). A within genotype regression of 2-hour INH concentrations on age showed a significant increase with age. A within genotype regression of 3-hour, 4-hour, and 5-hour concentrations on age also showed a significant increase with age in each instance. In ethnically similar adults, mean (SD) 2-hour INH concentrations (mg/l) for each genotype were significantly higher than the children's: SS 10.942 (1.740), FS 8.702 (1.841), and FF 6.031 (1.431).
CONCLUSIONS: Younger children eliminate INH faster than older children and, as a group, faster than adults, and require a higher mg/kg body weight INH dose to achieve serum concentrations comparable to adults.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15908628      PMCID: PMC1720436          DOI: 10.1136/adc.2004.052175

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  25 in total

1.  Genetic control of isoniazid metabolism in man.

Authors:  D A EVANS; K A MANLEY; V A McKUSICK
Journal:  Br Med J       Date:  1960-08-13

2.  Isoniazid pharmacokinetics in children according to acetylator phenotype.

Authors:  E Rey; D Gendrel; J M Treluyer; A Tran; A Pariente-Khayat; P d'Athis; G Pons
Journal:  Fundam Clin Pharmacol       Date:  2001-10       Impact factor: 2.748

3.  [Level of active isoniazid in the serum of tuberculous children].

Authors:  I Lupasco; G Algeorge; V Ghiu-Cimpeanu
Journal:  Poumon Coeur       Date:  1965

4.  [The pharmacokinetics of isoniazid in children (author's transl)].

Authors:  C Advenier; A Saint-Aubin; P Scheinmann; J Paupe
Journal:  Rev Fr Mal Respir       Date:  1981

5.  [Therapeutic consequences of measure of inactivation index of isoniazid during antituberculous therapy (author's transl)].

Authors:  G Houin; J P Tillement
Journal:  Therapie       Date:  1980 Sep-Oct       Impact factor: 2.070

Review 6.  Role of individual drugs in the chemotherapy of tuberculosis.

Authors:  D A Mitchison
Journal:  Int J Tuberc Lung Dis       Date:  2000-09       Impact factor: 2.373

7.  [Changes in the isoniazid inactivation index during antituberculosis treatment in children].

Authors:  J P Bouveret; J Hanoteau; J Gerbeaux; G Houin; J P Tillement
Journal:  Arch Fr Pediatr       Date:  1983-10

Review 8.  Clinical pharmacokinetics of isoniazid.

Authors:  W W Weber; D W Hein
Journal:  Clin Pharmacokinet       Date:  1979 Nov-Dec       Impact factor: 6.447

9.  Polymerase chain reaction with confronting two-pair primers for polymorphism genotyping.

Authors:  N Hamajima; T Saito; K Matsuo; K Kozaki; T Takahashi; K Tajima
Journal:  Jpn J Cancer Res       Date:  2000-09

10.  Microbial persistence. I. The capacity of tubercle bacilli to survive sterilization in mouse tissues.

Authors:  R M McCune; F M Feldmann; H P Lambert; W McDermott
Journal:  J Exp Med       Date:  1966-03-01       Impact factor: 14.307

View more
  54 in total

1.  In silico children and the glass mouse model: clinical trial simulations to identify and individualize optimal isoniazid doses in children with tuberculosis.

Authors:  Prakash M Jeena; William R Bishai; Jotam G Pasipanodya; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2010-11-22       Impact factor: 5.191

2.  Pharmacokinetics of First-Line Drugs Among Children With Tuberculosis in Rural Tanzania.

Authors:  Museveni Justine; Anita Yeconia; Ingi Nicodemu; Domitila Augustino; Jean Gratz; Estomih Mduma; Scott K Heysell; Sokoine Kivuyo; Sayoki Mfinanga; Charles A Peloquin; Theodore Zagurski; Gibson S Kibiki; Blandina Mmbaga; Eric R Houpt; Tania A Thomas
Journal:  J Pediatric Infect Dis Soc       Date:  2020-02-28       Impact factor: 3.164

3.  Evaluation of the Adequacy of the 2010 Revised World Health Organization Recommended Dosages of the First-line Antituberculosis Drugs for Children: Adequacy of Revised Dosages of TB Drugs for Children.

Authors:  Hongmei Yang; Anthony Enimil; Fizza S Gillani; Sampson Antwi; Albert Dompreh; Antoinette Ortsin; Eugene Adu Awhireng; Maxwell Owusu; Lubbe Wiesner; Charles A Peloquin; Awewura Kwara
Journal:  Pediatr Infect Dis J       Date:  2018-01       Impact factor: 2.129

4.  Low levels of pyrazinamide and ethambutol in children with tuberculosis and impact of age, nutritional status, and human immunodeficiency virus infection.

Authors:  S M Graham; D J Bell; S Nyirongo; R Hartkoorn; S A Ward; E M Molyneux
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

5.  Susceptibility of Mycobacterium bovis BCG vaccine strains to antituberculous antibiotics.

Authors:  Nicole Ritz; Marc Tebruegge; Tom G Connell; Aina Sievers; Roy Robins-Browne; Nigel Curtis
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

6.  Intracellular time course, pharmacokinetics, and biodistribution of isoniazid and rifabutin following pulmonary delivery of inhalable microparticles to mice.

Authors:  Rahul Kumar Verma; Jatinder Kaur; Kaushlendra Kumar; Awadh Bihari Yadav; Amit Misra
Journal:  Antimicrob Agents Chemother       Date:  2008-06-30       Impact factor: 5.191

Review 7.  A Critical Review of the Current Evidence for Measuring Drug Concentrations of First-Line Agents Used to Treat Tuberculosis in Children.

Authors:  Kyle John Wilby; Sara Shabana; Mary H H Ensom; Fawziah Marra
Journal:  Clin Pharmacokinet       Date:  2016-01       Impact factor: 6.447

8.  Is there any difference between acetylator phenotypes in tuberculosis patients and healthy subjects?

Authors:  Hossein Khalili; Simin Dashti-Khavidaki; Mohsen Amini; Reza Mahjub; Mahboobeh Hajiabdolbaghi
Journal:  Eur J Clin Pharmacol       Date:  2010-03       Impact factor: 2.953

9.  Anti-tuberculosis treatments and risk of hepatocellular carcinoma in tuberculosis patients with liver cirrhosis: a population-based case-control study.

Authors:  Y-P Lim; C-L Lin; D-Z Hung; Y-N Lin; C-H Kao
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-09-27       Impact factor: 3.267

10.  Pharmacokinetics of first-line antituberculosis drugs in HIV-infected children with tuberculosis treated with intermittent regimens in India.

Authors:  Geetha Ramachandran; A K Hemanth Kumar; P K Bhavani; T Kannan; S Ramesh Kumar; N Poorana Gangadevi; V V Banurekha; L Sekar; N Ravichandran; G Mathevan; G N Sanjeeva; Rajeshwar Dayal; Soumya Swaminathan
Journal:  Antimicrob Agents Chemother       Date:  2014-12-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.